A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

NCT07092865 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

184

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: Adjuvanted RSVPreF3 vaccine

Sponsor

GlaxoSmithKline